Orexo's share is listed on NasdaqOMX Stockholm, Sweden (ORX), and is available as American Depository Receipts on OTCQX market in the US (OXROY).
Share price
Name
0.00
0 SEK (0%)
HH:MM CET • 20YY-MM-DD
Latest presentations
Analyst reports
Investment themes
Latest CEO Comments
JULY 14, 2022
"Good tailwind in the financial development"
Read the latest CEO comments from Nikolaj Sørensen
News flow
Press Releases and News
Orexo’s partner Gesynta Pharma has announced phase II study results from the OX-MPI (GS-248) project
Orexo’s partner Trinity Health today announces the availability of vorvida® and deprexis® to patients
First patent issued in Europe for Orexo’s adrenaline product OX640
Orexo to participate in Pareto Securities´ 13th Annual Healthcare Conference
Key financial figures
Group net revenue
597 MSEK
Last Twelve Months, Q321-Q222
Group EBITDA
-126 MSEK
Last Twelve Months, Q321-Q222
US Pharma segment EBIT
312 MSEK
Last Twelve Months, Q321-Q222
Cash position
468 MSEK
Q222
